AI tool helps doctors find brain aneurysms

Stanford researchers have developed an AI tool that can help diagnose damaging brain aneurysms that can have potentially fatal effects.

The development of the tool was detailed in a paper published June 7 in JAMA Network Open that examined a diagnostic study of intracranial aneurysms.

Researchers used a test set of 115 examinations that were reviewed for the presence of an aneurysm with model augmentation and once without in a randomized order by eight clinicians. Compared to the reviews without augmentation, the examinations with augmentation were more sensitive and accurate, helping clinicians make a difficult diagnosis.

The tool developed in the study was built around an algorithm called HeadXNet, and helped clinicians find about six more aneurysms in 100 scans that contain them. To train the algorithm, researchers used 611 computerized tomography angiogram head scans that had clinically significant aneurysms.

With high health stakes associated with aneurysms, including stroke or death, having another tool to help doctors save lives in this area is “highly desirable,” the researchers stated in their study. For example, aneurysm rupture is fatal in 40% of patients, while two-thirds of those who survive end up with an irreversible neurological disability.

“Search for an aneurysm is one of the most labor-intensive and critical tasks radiologists undertake,” Kristen Yeom, associate professor of radiology and co-senior author of the paper, said in a statement. “Given inherent challenges of complex neurovascular anatomy and potential fatal outcome of a missed aneurysm, it prompted me to apply advances in computer science and vision to neuroimaging.”

Without augmentation, clinicians achieved a microaveraged sensitivity of 0.831, specificity of 0.96 and an accuracy of 0.893, compared to microaveraged sensitivity of 0.89, specificity of 0.975 and accuracy of 0.932 with augmentation.

While the algorithm isn’t intended to replace the role of a doctor when making these diagnoses, the AI tool can help comb brain scans faster and diagnose trickier images.

“There’s been a lot of concern about how machine learning will actually work within the medical field,” Allison Park, Stanford graduate student in statistics and co-lead author of the paper, said in a statement. “This research is an example of how humans stay involved in the diagnostic process, aided by an artificial intelligence tool.”

Still, the Stanford researchers argued that more studies should be done to evaluate the generalizability of their AI tool before it’s used in real-time settings.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.